A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

NCT02034097 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped GSK has decided to terminate the Product Development of foretinib and conclude our Development Agreement with Exelixis

Conditions

Cancer

Interventions

DRUG: Foretinib
DRUG: Erlotinib

Sponsor

GlaxoSmithKline